Bevacizumab Improves the Efficacy of 5-Fluorouracil/Leucovorin in Patients with Advanced Colorectal Cancer

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 Kabbinavar, 2004, Results of a randomized, phase II controlled trial of bevacizumab in combination with 5-fluorouracil and leucovorin as first-line therapy in subjects with metastatic CRC, Proc Am Soc Clin Oncol, 23, 249 Mass, 2004, Bevacizumab in combination with 5-FU /leucovorin improves survival in patients with metastatic colorectal cancer: a combined analysis, Proc Am Soc Clin Oncol, 23, 274 Hurwitz, 2004, Bevacizumab in combination with 5-fluorouracil and leucovorin: a promising regimen for first-line metastatic colorectal cancer, Program and Proceedings of the 2004 Gastrointestinal Cancers Symposium, 182 Chen, 2004, Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: an NCI Treatment Referral Center trial (TRC-0301), Proc Am Soc Clin Oncol, 23, 249